8-KLeadership ChangesExhibits & Filings

Guardant Health, Inc. 8-K Report, Executive Changes (Aug 5, 2021)

Filed August 5, 2021For Securities:GH

Summary

Guardant Health, Inc. announced significant leadership changes on August 5, 2021, establishing a Co-Chief Executive Officer (Co-CEO) structure. Dr. AmirAli Talasaz has been appointed Co-CEO alongside the current CEO, Helmy Eltoukhy. Dr. Talasaz will now oversee the screening division, while Dr. Eltoukhy will lead the oncology division. Dr. Talasaz is stepping down as COO but will remain President. This leadership split is intended to allow for focused strategic direction within the company's key operational areas. Additionally, Dr. Eltoukhy has assumed the role of Chairperson of the Board, while Dr. Talasaz has resigned from the Chairperson position but will continue as a Board member. The company also announced the appointment of Meghan Joyce to its Board of Directors, increasing the board size to eight. Ms. Joyce, COO and EVP of Platform at Oscar Health, brings extensive experience in health tech and operations. She has been appointed to the audit and compensation committees, and her expertise is expected to strengthen the board's oversight and strategic guidance. Ms. Joyce will receive standard non-employee director compensation, including stock options and RSUs, designed to align her interests with those of shareholders.

Key Highlights

  • 1Guardant Health adopts a Co-CEO leadership model with AmirAli Talasaz and Helmy Eltoukhy sharing top executive responsibilities.
  • 2Dr. Talasaz will lead the screening division, while Dr. Eltoukhy will focus on the oncology division, indicating a strategic split of operational oversight.
  • 3Helmy Eltoukhy has been appointed as the new Chairperson of the Board, succeeding Dr. Talasaz.
  • 4AmirAli Talasaz resigns as COO but remains President and a Board member.
  • 5Meghan Joyce has been appointed as a new Class II director to the Board, expanding its size to eight members.
  • 6Ms. Joyce, with a background at Oscar Health and Uber, has been appointed to the Audit and Compensation Committees.
  • 7Ms. Joyce will receive standard director compensation, including stock options and RSUs valued at $362,500, vesting over time.

Frequently Asked Questions

The Co-CEO structure is intended to allow for a more focused leadership approach, with Dr. Helmy Eltoukhy leading the oncology division and Dr. AmirAli Talasaz overseeing the screening division. This split aims to leverage their respective strengths and provide dedicated leadership to key areas of the business.

Dr. Talasaz has been appointed Co-CEO and will lead the screening division. He has resigned as Chief Operating Officer (COO) but will continue to serve as President of the company and retain his seat on the Board of Directors. He has also resigned as Chairperson of the Board.

Meghan Joyce is a newly appointed Class II director to Guardant Health's Board. She brings significant experience from her role as COO and EVP of Platform at Oscar Health and previous leadership positions at Uber. She has been appointed to the audit and compensation committees, suggesting a focus on financial oversight and executive compensation.

According to the filing, the compensation for both Dr. Helmy Eltoukhy and Dr. AmirAli Talasaz will remain unchanged in their new roles as Co-CEOs.